A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-01

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to study the effect of resveratrol on the improvement of lipid and uric acid metabolism, randomized intervention trials were conducted to compare the effects of resveratrol on the improvement of lipid and uric acid metabolism in different dose groups. To explore the best dose of resveratrol for the prevention and treatment of metabolic diseases provide an important scientific basis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation

NCT02219906

Metabolic Syndrome

COMPLETED NA

Oral Glutathione Supplementation on the Levels of Blood Glutathione

NCT01044277

Healthy Adults

COMPLETED NA

Dietary Effects of Sulfur Amino Acids

NCT00228618

Healthy

COMPLETED

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

NCT02583672

Gaucher Disease Type 1

COMPLETED PHASE2

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432

Obesity Hyperlipidemia Insulin Resistance +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In order to study the effect of resveratrol on the improvement of lipid and uric acid metabolism, randomized controlled trials were conducted to enrolled 160 patients with dyslipidemia. The subjects were divided into 0 mg / d, 100 mg / d, 300 mg / d, 600 mg/ d four dose groups, intervention for 8 weeks, comparing different doses of resveratrol on lipid and uric acid metabolism. To explore the best dose of resveratrol for the prevention and treatment of metabolic diseases provide an important scientific basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).

Intervention: Drug: Mega Resveratrol® capsules

Group Type PLACEBO_COMPARATOR

Mega Resveratrol® Placebo capsules

Intervention Type DRUG

Mega Resveratrol® Placebo capsules

100mg/d resveratrol

During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.

Intervention: Drug: Mega Resveratrol® capsules

Group Type EXPERIMENTAL

Mega Resveratrol® capsules

Intervention Type DRUG

Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

300mg/d resveratrol

During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.

Intervention: Drug: Mega Resveratrol® capsules

Group Type EXPERIMENTAL

Mega Resveratrol® capsules

Intervention Type DRUG

Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

600mg/d resveratrol

During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.

Intervention: Drug: Mega Resveratrol® capsules

Group Type EXPERIMENTAL

Mega Resveratrol® capsules

Intervention Type DRUG

Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mega Resveratrol® capsules

Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

Intervention Type DRUG

Mega Resveratrol® Placebo capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dyslipidemia
* The age between 35 and 70 years old

Exclusion Criteria

* Intake of any medicine that affect lipid metabolism currently or in the preceding 6 months
* Dietary supplementation with phytochemicals including resveratrol in the preceding 3 months
* History of acute or chronic infectious disease, autoimmune disease, cancer, traumatic injury, or surgery in the preceding 1 month
* History of severe chronic disease including AS and CVD, liver or renal dysfunction, and lactation or pregnancy
* Pregnant woman and Breast Feeding Women

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes